WGC Irb — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2022	Research	$9,465	7
2021	Research	$22,609	17

Breakdown

Who paid Research payments · program years 2021–2022

MacroGenics, Inc. $20,469 14 payments
AveXis $6,755 5 payments
ADC Therapeutics America, Inc. $3,955 3 payments
Myovant Sciences Inc. $895 2 payments

Studies the money was for Research payments · program years 2021–2022

Combination Margetuximab, Incmga00012, Mgd013, and Chemotherapy Phase 2 3 Trial in Her2 Gastric Gej Cancer Mahogany $20,469 14 payments
A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 $6,755 5 payments
A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3) $3,955 3 payments
An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids $895 2 payments

What the money was spent on Research payments · program years 2021–2022

Non-patient care $13,794 10 payments
Overhead $6,675 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.